Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome

Journal of Gastroenterology and Hepatology (Australia)

Volumn 22, Issue 8, 2007, Pages 1183-1189

  Harish, Kareem ^a   Hazeena, Kizhekkan ^a   Thomas, Varghese ^a   Kumar, Sunil ^a   Jose, Tony ^a   Narayanan, Puthiyaveetil ^a  

^a GOVERNMENT MEDICAL COLLEGE   (India)

Author keywords

Colonic transit time; Constipation; Constipation predominant; Irritable bowel syndrome; Male; Tegaserod

Indexed keywords

PLACEBO; TEGASEROD;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFECATION HABIT; DOUBLE BLIND PROCEDURE; DRUG EFFECT; HUMAN; INTESTINE TRANSIT TIME; IRRITABLE COLON; MALE; PATIENT SATISFACTION; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL;

EID: 34547698761     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2006.04543.x     Document Type: Article

References (39)

1. Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology 2002 123 : 2108 31.
2. McKee DP, Quigley EM. Intestinal motility in irritable bowel syndrome: is IBS a motility disorder? Part 1. Definition of IBS and colonic motility. Dig. Dis. Sci. 1993 38 : 1761 72.
3. Cann PA, Read NW, Brown C, Hobson N, Holdsworth CD. Irritable bowel syndrome: relationship of disorders in the transit of a single solid meal to symptom patterns. Gut 1983 24 : 405 11.
4. Kellow JE, Phillips SF. Altered small bowel motility in irritable bowel syndrome is correlated with symptoms. Gastroenterology 1987 92 : 1885 93.
5. Nguyen A, Camilleri M, Kost LJ et al. SDZ HTF 919 stimulates canine colonic motility and transit in vivo. J. Pharmacol. Exp. Ther. 1997 280 : 1270 6.
6. Jin JG, Foxx-Orenstein AE, Grider JR. Propulsion in guinea pig colon induced by 5-hydroxytryptamine (HT) via 5-HT4 and 5-HT3 receptors. J. Pharmacol. Exp. Ther. 1999 288 : 93 7.
7. Appel S, Kumle A, Hubert M, Duvauchelle T. First pharmacokinetic- pharmacodynamic study in humans with a selective 5-hydroxytryptamine4-receptor agonist. J. Clin. Pharmacol. 1997 37 : 229 37.
8. Appel S, Kumle A, Meier R. Clinical pharmacodynamics of SDZ HTF 919, a new 5-HT4 receptor agonist, in a model of slow colonic transit. Clin. Pharmacol. Ther. 1997 62 : 546 55.
9. Degen L, Matzinger D, Merz M et al. Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment. Pharmacol. Ther. 2001 15 : 1745 51.
10. Muller-Lissner SA, Fumagalli I, Bardhan KD et al. Tegaserod, a 5-HT (4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment. Pharmacol. Ther. 2001 15 : 1655 66.
11. Novick J, Miner P, Krause R et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment. Pharmacol. Ther. 2002 16 : 1877 88.
12. Kellow J, Lee OY, Chang FY et al. An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 2003 52 : 671 6.
13. Nyhlin H, Bang C, Elsborg L et al. A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome. Scand. J. Gastroenterol. 2004 39 : 119 26.
14. Kamm MA, Muller-Lissner S, Talley NJ et al. Tegaserod for the treatment of chronic constipation: a randomized, double-blind, placebo-controlled multinational study. Am. J. Gastroenterol. 2005 100 : 362 72.
15. Johanson J, Wald A, Tougas G et al. Effect of tegaserod in chronic constipation: a randomized, double-blind, controlled trial. Clin. Gastroenterol. Hepatol. 2004 2 : 796 805.
16. Appel-Dingemanse S. Clinical pharmacokinetics of tegaserod, a serotonin 5-HT (4) receptor partial agonist with promotile activity. Clin. Pharmacokinet. 2002 41 : 1021 42.
17. Prather CM, Camilleri M, Zinsmeister AR, McKinzie S, Thomforde G. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000 118 : 463 8.
18. Drossman DA. The Rome II modular questionnaire. In: Drossman DA, Corazziari E, Talley NJ, Thompson WG, Whitehead WE, eds. Rome II - The Functional Gastrointestinal Disorders; Diagnosis, Pathophysiology and Treatment: A Multinational Consensus. McLean VA : Degnon Associates, 2000 360.
19. Chaussade S, Khyari A, Roche H et al. Determination of total and segmental colonic transit time in constipated patients. Results in 91 patients with a new simplified method. Dig. Dis. Sci. 1989 34 : 1168 72.
20. Metcalf AM, Phillips SF, Zinsmeister AR, MacCarty RL, Beart RW, Wolff BG. Simplified assessment of segmental colonic transit. Gastroenterology 1987 92 : 40 7.
21. Nabar AA, Bhatia SJ, Abraham P, Ravi P, Mistry FP. Total and segmental colonic transit time in non ulcer dyspepsia. Indian J. Gastroenterol. 1995 14 : 131 3.
22. Arhan P, Devroede G, Jehannin B et al. Segmental colonic transit time. Dis. Colon Rectum 1981 24 : 625 9.
23. Briejer MR, Schuurkes JA, Sarna SK. Idiopathic constipation: too few stools and too little knowledge. Trends Pharmacol. Sci. 1999 20 : 1 3.
24. Muller-Lissner S, Koch G, Talley NJ et al. Subject's Global Assessment of Relief: an appropriate method to assess the impact of treatment on irritable bowel syndrome-related symptoms in clinical trials. J. Clin. Epidemiol. 2003 56 : 310 16.
25. Spiller RC. Problems and challenges in the design of irritable bowel syndrome clinical trials: experience from published trials. Am. J. Med. 1999 107 : 91S 97S.
26. Patel SM, Stason WB, Legedza A et al. The placebo effect in irritable bowel syndrome trials: a meta-analysis. Neurogastroenterol. Motil. 2005 17 : 332 40.
27. Van der Sijp JR, Kamm MA, Nightingale JM et al. Radioisotope determination of regional colonic transit in severe constipation: comparison with radio opaque markers. Gut 1993 34 : 402 8.
28. Iida M, Ikeda M, Kishimoto M et al. Evaluation of gut motility in type II diabetes by the radiopaque marker method. J. Gastroenterol. Hepatol. 2000 15 : 381 5.
29. Geders JM, Gaing A, Bauman WA, Korsten MA. The effect of cisapride on segmental colonic transit time in patients with spinal cord injury. Am. J. Gastroenterol. 1995 90 : 285 9.
30. El-Salhy M, Norrgard O, Spinnell S. Abnormal colonic endocrine cells in patients with chronic idiopathic slow-transit constipation. Scand. J. Gastroenterol. 1999 34 : 1007 11.
31. Crowell MD. The role of serotonin in the pathophysiology of irritable bowel syndrome. Am. J. Manag. Care 2001 7 : S252 60.
32. Gershon MD. Serotonin and its implication for the management of irritable bowel syndrome. Rev. Gastroenterol. Disord. 2003 3 : S25 34.
33. Berrada D, Canenguez K, Lembo T. New approaches to the medical treatment of irritable bowel syndrome. Curr. Gastroenterol. Rep. 2003 5 : 337 42.
34. Ahn J, Ehrenpreis ED. Emerging treatments for irritable bowel syndrome. Expert Opin. Pharmacother. 2002 3 : 9 21.
35. Grider JR, Foxx-Orenstein AE, Jin JG. 5-Hydroxytryptamine4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine. Gastroenterology 1998 115 : 370 80.
36. Appel-Dingemanse S, Horowitz A, Campestrini J, Osborne S, McLeod J. The pharmacokinetics of the novel promotile drug, tegaserod, are similar in healthy subjects-male and female, elderly and young. Aliment. Pharmacol. Ther. 2001 15 : 937 44.
37. Chang L, Naliboff BD, Schmulson M et al. The role of gender and bowel habit predominance on visceral perception in IBS. Gastroenterology 2001 120 : A755.
38. Naliboff BD, Berman S, Chang L et al. Sex-related differences in IBS patients: central processing of visceral stimuli. Gastroenterology 2003 124 : 1738 47.
39. Viramontes BE, Camilleri M, McKinzie S et al. Gender-related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome. Am. J. Gastroenterol. 2001 96 : 2671 9.